| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 76.29 mm | 76.29 mm | 76.29 mm | 76.29 mm | 76.29 mm | 76.29 mm |
| Cash burn (monthly) | (no burn) | 1.46 mm | 6.20 mm | 92.00 k | (no burn) | 1.46 mm |
| Cash used (since last report) | n/a | 7.43 mm | 31.50 mm | 467.53 k | n/a | 7.43 mm |
| Cash remaining | n/a | 68.86 mm | 44.79 mm | 75.82 mm | n/a | 68.86 mm |
| Runway (months of cash) | n/a | 47.1 | 7.2 | 824.2 | n/a | 47.1 |
| 13F holders | Current |
|---|---|
| Total holders | 43 |
| Opened positions | 6 |
| Closed positions | 16 |
| Increased positions | 2 |
| Reduced positions | 9 |
| 13F shares | Current |
|---|---|
| Total value | 14.29 bn |
| Total shares | 27.37 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| GSK GSK | 9.19 mm | $18.66 mm |
| Anson Funds Management | 3.75 mm | $5.03 bn |
| PFE Pfizer | 2.36 mm | $32.98 mm |
| Vanguard | 1.76 mm | $2.36 bn |
| Atlas Venture Fund IX | 1.38 mm | $22.05 mm |
| Acadian Asset Management | 1.07 mm | $1.44 mm |
| Atlas Venture Fund X | 1.03 mm | $20.98 mm |
| Renaissance Technologies | 974.65 k | $1.31 bn |
| GOOG Alphabet | 889.98 k | $1.19 bn |
| GV 2015 | 889.98 k | $17.26 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 Feb 25 | Mahadevia Ankit | Common Stock | Sell | Dispose S | No | No | 0.78 | 55,260 | 43.10 k | 689,866 |
| 5 Feb 25 | Mahadevia Ankit | Common Stock | Sell | Dispose S | No | No | 0.78 | 13,959 | 10.89 k | 745,126 |
| 5 Feb 25 | Sath Shukla | Common Stock | Sell | Dispose S | No | No | 0.78 | 106,408 | 83.00 k | 1,736,883 |
| 5 Feb 25 | Sath Shukla | Common Stock | Sell | Dispose S | No | No | 0.78 | 42,786 | 33.37 k | 1,843,291 |
| 5 Feb 25 | Sath Shukla | Common Stock | Sell | Dispose S | No | No | 0.78 | 6,139 | 4.79 k | 1,886,077 |
| 5 Feb 25 | Esther Rajavelu | Common Stock | Sell | Dispose S | No | No | 0.78 | 20,689 | 16.14 k | 724,720 |
| 5 Feb 25 | Timothy Keutzer | Common Stock | Sell | Dispose S | No | No | 0.78 | 24,920 | 19.44 k | 741,439 |
| 5 Feb 25 | Timothy Keutzer | Common Stock | Sell | Dispose S | No | No | 0.78 | 27,643 | 21.56 k | 766,359 |
| 5 Feb 25 | Timothy Keutzer | Common Stock | Sell | Dispose S | No | No | 0.78 | 3,974 | 3.10 k | 794,002 |
| 3 Feb 25 | Sath Shukla | Common Stock | Grant | Acquire A | No | No | 0 | 751,407 | 0.00 | 1,892,216 |
